AbbVie (ABBV) Tops Q2 EPS by 6c; Boosts FY16 EPS Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. TSLA
4. NVDA
5. GNK
6. USO
7. AWK
8. MU
9. ARGX
10. SPCX

Go back to AbbVie (ABBV) Tops Q2 EPS by 6c; Boosts FY16 EPS Outlook

BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain

July 29, 2016 11:54 AM EDT

BMO Capital affirms AbbVie (NYSE: ABBV) at Market Perform with a price target of $66 following Q2 results out earlier Friday.

Analyst Alex Arfaei commented, revenue was 3.7% above consensus, driven by higher sales of Humira and Imbruvica, while OPEX was... More

AbbVie (ABBV) Initiates Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory

July 28, 2016 5:32 PM EDT

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome... More